| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S Werner, E af Trampe, P Palacios, I Lax, K Hal. Growth hormone producing pituitary adenomas with concomitant hypersecretion of prolactin are particularly sensitive to photon irradiation. International journal of radiation oncology, biology, physics. vol 11. issue 9. 1985-10-04. PMID:4030438. |
radiotherapy, 3 years after treatment, appeared to be equivalent to the primary surgical intervention in reducing gh and sma in patients with acromegaly due to advanced macroadenomas. |
1985-10-04 |
2023-08-11 |
Not clear |
| K Y Ho, W S Evans, M O Thorne. Disorders of prolactin and growth hormone secretion. Clinics in endocrinology and metabolism. vol 14. issue 1. 1985-09-26. PMID:3926353. |
the abnormal gh responses to glucose and trh support the diagnosis, but by themselves should not be considered to be diagnostic of acromegaly. |
1985-09-26 |
2023-08-11 |
human |
| P Beck-Peccoz, M Bassetti, A Spada, G Medri, M Arosio, G Giannattasio, G Fagli. Glycoprotein hormone alpha-subunit response to growth hormone (GH)-releasing hormone in patients with active acromegaly. Evidence for alpha-subunit and GH coexistence in the same tumoral cell. The Journal of clinical endocrinology and metabolism. vol 61. issue 3. 1985-09-16. PMID:2410443. |
glycoprotein hormone alpha-subunit response to growth hormone (gh)-releasing hormone in patients with active acromegaly. |
1985-09-16 |
2023-08-11 |
human |
| H M Schulte, G Benker, R Windeck, T Olbricht, D Reinwei. Failure to respond to growth hormone releasing hormone (GHRH) in acromegaly due to a GHRH secreting pancreatic tumor: dynamics of multiple endocrine testing. The Journal of clinical endocrinology and metabolism. vol 61. issue 3. 1985-09-16. PMID:3926812. |
patients with untreated acromegaly due to a pituitary tumor respond to exogenous administration of ghrh with a further rise of their elevated basal growth hormone (gh) levels. |
1985-09-16 |
2023-08-11 |
Not clear |
| A L Hulting, J Wersäll, S Werne. Evidence of a circulating growth hormone stimulating factor other than growth hormone releasing hormone in a patient with pituitary tumour and acromegaly. Acta endocrinologica. vol 109. issue 3. 1985-09-09. PMID:3927648. |
this study is a report on the growth hormone (gh) stimulatory effect of serum and plasma from a patient with notably active acromegaly due to a gh producing pituitary adenoma. |
1985-09-09 |
2023-08-11 |
human |
| A L Hulting, J Wersäll, S Werne. Evidence of a circulating growth hormone stimulating factor other than growth hormone releasing hormone in a patient with pituitary tumour and acromegaly. Acta endocrinologica. vol 109. issue 3. 1985-09-09. PMID:3927648. |
in contrast, gh release was increased in 9/10 patients, when media contained serum or plasma from the patient with notably active acromegaly. |
1985-09-09 |
2023-08-11 |
human |
| E Moyse, M Le Dafniet, J Epelbaum, P Pagesy, F Peillon, C Kordon, A Enjalber. Somatostatin receptors in human growth hormone and prolactin-secreting pituitary adenomas. The Journal of clinical endocrinology and metabolism. vol 61. issue 1. 1985-07-23. PMID:2860120. |
finally, in acromegaly, the density of [125i-tyr]srih-binding sites in the adenomas was negatively correlated with plasma gh levels before surgery (r = -0.80). |
1985-07-23 |
2023-08-11 |
human |
| G P Ceda, A R Hoffman, G D Silverberg, D M Wilson, R G Rosenfel. Regulation of growth hormone release from cultured human pituitary adenomas by somatomedins and insulin. The Journal of clinical endocrinology and metabolism. vol 60. issue 6. 1985-06-24. PMID:3889029. |
thus, these data suggest that somatomedins may exert feedback inhibition of gh secretion in some patients with acromegaly. |
1985-06-24 |
2023-08-11 |
human |
| S W Lamberts, J G Klijn, C C van Vroonhoven, S Z Stefank. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas. The Journal of clinical endocrinology and metabolism. vol 60. issue 6. 1985-06-24. PMID:3923021. |
there is great variability in the gh secretory responses to different stimuli in patients with acromegaly. |
1985-06-24 |
2023-08-11 |
Not clear |
| S W Lamberts, J G Klijn, C C van Vroonhoven, S Z Stefank. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas. The Journal of clinical endocrinology and metabolism. vol 60. issue 6. 1985-06-24. PMID:3923021. |
we conclude that in acromegaly, the presence of prl within the gh-secreting pituitary adenoma makes gh secretion more sensitive to bromocriptine and trh, while normal sensitivity to hypothalamus-mediated stimulation (alpha-adrenergic agonist) is retained to some extent. |
1985-06-24 |
2023-08-11 |
Not clear |
| P C Eskildsen, E Hommel, J Buchhav. The effect of a new ergoline derivative, CU 32-085, in the treatment of acromegaly. A controlled study. Clinical endocrinology. vol 22. issue 2. 1985-06-19. PMID:3886207. |
we conclude that cu 32-085 caused a marked suppression of the release of gh and prl and an improvement of the major symptoms of acromegaly, a therapeutic effect that is comparable to the previous experience with bromocriptine. |
1985-06-19 |
2023-08-11 |
Not clear |
| J W Nortier, R J Croughs, J H Thijssen, F Schwar. Bromocriptine therapy in acromegaly: effects on plasma GH levels, somatomedin-C levels and clinical activity. Clinical endocrinology. vol 22. issue 2. 1985-06-19. PMID:4039234. |
bromocriptine therapy in acromegaly: effects on plasma gh levels, somatomedin-c levels and clinical activity. |
1985-06-19 |
2023-08-11 |
Not clear |
| J W Nortier, R J Croughs, J H Thijssen, F Schwar. Bromocriptine therapy in acromegaly: effects on plasma GH levels, somatomedin-C levels and clinical activity. Clinical endocrinology. vol 22. issue 2. 1985-06-19. PMID:4039234. |
it is concluded that measurement of plasma gh levels still appears to be the most useful biochemical assessment of disease activity in bromocriptine-treated acromegaly. |
1985-06-19 |
2023-08-11 |
Not clear |
| K Hanew, A Sasaki, S Sato, M Goh, Y Shimizu, O Murakami, K Yoshinag. Modulation of postinhibitory rebound rise in plasma GH by hypothalamic hormones in patients with acromegaly. Endocrinologia japonica. vol 31. issue 6. 1985-06-11. PMID:6152422. |
modulation of postinhibitory rebound rise in plasma gh by hypothalamic hormones in patients with acromegaly. |
1985-06-11 |
2023-08-12 |
human |
| K Hanew, A Sasaki, S Sato, M Goh, Y Shimizu, O Murakami, K Yoshinag. Modulation of postinhibitory rebound rise in plasma GH by hypothalamic hormones in patients with acromegaly. Endocrinologia japonica. vol 31. issue 6. 1985-06-11. PMID:6152422. |
dopamine (da) infusion (5 micrograms/kg/min for 90 min) also induced similar inhibition and postinhibitory rebound rises in gh secretion in 7 patients with acromegaly. |
1985-06-11 |
2023-08-12 |
human |
| K Hanew, S Sato, A Sasaki, Y Shimizu, O Murakami, K Yoshinag. Comparative study on the responses of plasma GH to synthetic GH-releasing factor and other stimulatory and inhibitory agents in patients with acromegaly. The Tohoku journal of experimental medicine. vol 145. issue 2. 1985-06-10. PMID:2859672. |
comparative study on the responses of plasma gh to synthetic gh-releasing factor and other stimulatory and inhibitory agents in patients with acromegaly. |
1985-06-10 |
2023-08-11 |
human |
| K Hanew, S Sato, A Sasaki, Y Shimizu, O Murakami, K Yoshinag. Comparative study on the responses of plasma GH to synthetic GH-releasing factor and other stimulatory and inhibitory agents in patients with acromegaly. The Tohoku journal of experimental medicine. vol 145. issue 2. 1985-06-10. PMID:2859672. |
ten patients with active acromegaly received synthetic human pancreatic gh releasing factor (hpghrf-44), and the gh responses to ghrf were compared with the basal gh levels and with the gh responses to arginine, trh, lh-rh, somatostatin, and l-dopa. |
1985-06-10 |
2023-08-11 |
human |
| K von Werder, M Losa, G K Stalla, L Bock, O A Mülle. Human pancreatic growth hormone releasing factor (hpGRF): GRF- and GH-levels after bolus injection and infusion of hpGRF. Acta neurochirurgica. vol 75. issue 1-4. 1985-06-06. PMID:2986424. |
100 micrograms hpgrf was given to 14 patients with active acromegaly leading to a significant rise of the gh levels with the exception of 3 patients. |
1985-06-06 |
2023-08-11 |
human |
| T B Hart, S K Radow, W G Blackard, H S Tucker, K R Coope. Sleep apnea in active acromegaly. Archives of internal medicine. vol 145. issue 5. 1985-06-06. PMID:3994462. |
ten patients had active acromegaly (mean gh concentration, 62.2 ng/ml; range, 12.6 to 148 ng/ml), while 11 patients had inactive acromegaly (mean gh, 3.2 ng/ml; range, 0.7 to 6.4 ng/ml). |
1985-06-06 |
2023-08-11 |
Not clear |
| T B Hart, S K Radow, W G Blackard, H S Tucker, K R Coope. Sleep apnea in active acromegaly. Archives of internal medicine. vol 145. issue 5. 1985-06-06. PMID:3994462. |
we conclude that sas is associated with active acromegaly and that the gh level does not affect the hypercapnic ventilatory response. |
1985-06-06 |
2023-08-11 |
Not clear |